The DHR-flow cytometric assay is the laboratory gold standard for screening CGD, with genetic testing available to confirm CGD when mutations are found in CYBB, CYBA, NCF1, NCF2, NCF4, and CYBC1 (13). This evidence concerns the gene NCF2 and chronic granulomatous disease.